HRTX — Heron Therapeutics Income Statement
0.000.00%
- $527.29m
- $605.30m
- $127.04m
- 40
- 25
- 88
- 49
Annual income statement for Heron Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 146 | 88.6 | 86.3 | 108 | 127 |
Cost of Revenue | |||||
Gross Profit | 84.3 | 52.4 | 40.3 | 52.8 | 61.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 357 | 317 | 304 | 282 | 238 |
Operating Profit | -211 | -228 | -218 | -175 | -111 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -205 | -227 | -221 | -182 | -111 |
Net Income After Taxes | -205 | -227 | -221 | -182 | -111 |
Net Income Before Extraordinary Items | |||||
Net Income | -205 | -227 | -221 | -182 | -111 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -205 | -227 | -221 | -182 | -111 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.5 | -2.5 | -2.24 | -1.67 | -0.8 |